Search

Displaying results 2591 - 2600 of 4234 in total
  1. Drug

    Mirabegron

    go.drugbank.com/drugs/DB08893
    ApprovedInvestigational

    It is unique amongst overactive bladder treatment options in that, unlike other treatments such as [solifenacin] and [darifenacin], it lacks significant antimuscarinic activity,[A232553] which is responsible … Mirabegron has a comparatively favorable adverse effect profile as compared to other available treatment options, and its complementary mechanism to the antimuscarinics that came before it allows for its

  2. Drug

    Oveporexton

    go.drugbank.com/drugs/DB21680
    Approved

    [L64068,L64069] Unlike existing narcolepsy treatments such as stimulants and sedatives, which manage individual symptoms, oveporexton acts on the underlying orexin deficiency that drives the disorder. … [L64069] Oveporexton has been recommended for scheduling as a controlled substance, and its final controlled-substance schedule and commercial availability are pending a determination by the Drug Enforcement

  3. Drug

    Asfotase alfa

    go.drugbank.com/drugs/DB09105
    ApprovedInvestigational

    Asfotase alfa is a first-in-class bone-targeted enzyme replacement therapy designed to address the underlying cause of hypophosphatasia (HPP)—deficient alkaline phosphatase (ALP). Hypophosphatasia is almost always fatal when severe skele...

  4. Drug

    Propiomazine

    go.drugbank.com/drugs/DB00777
    Approved

    Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment...

  5. Drug

    Pirenzepine

    go.drugbank.com/drugs/DB00670
    ApprovedWithdrawn

    It also potentiates the effect of other antiulcer agents such as cimetidine and ranitidine. It is generally well tolerated by patients.

  6. Drug

    Dithiazanine

    go.drugbank.com/drugs/DB11516
    ApprovedVet approvedWithdrawn

    Dithiazanine iodide has been withdrawn from the market in countries such as France in Italy, but it may remain available in others.[A254427,L44032]

  7. Drug

    Benzhydrocodone

    go.drugbank.com/drugs/DB15465
    Approved

    [L4894] It was developed in an effort to reduce parenteral bioavailability of the active metabolite as a deterrent to abuse.

  8. Drug

    Potassium citrate

    go.drugbank.com/drugs/DB09125
    ApprovedInvestigationalVet approved

    Potassium citrate (also known as tripotassium citrate) is a potassium salt of citric acid. It is a white, hygroscopic crystalline powder. It is odorless with a saline taste.

  9. Drug

    Elranatamab

    go.drugbank.com/drugs/DB15395
    ApprovedInvestigational

    Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. It is a humanized immunoglobulin 2-alanine kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb, each...

    Synonyms: -CHAIN) (HUMAN-MUS MUSCULUS MONOCLONAL PF-06863059 .GAMMA.2-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL PF-06863059 .KAPPA.-CHAIN, (223->217')(2, IMMUNOGLOBULIN G2-KAPPA, ANTI-(HOMO SAPIENS T-CELL SURFACE GLYCOPROTEIN CD3 EPSILON CHAIN CD3E (T-CELL SURFACE ANTIGEN T3/LEU-4 EPSILON CHAIN)), HUMAN-MUS MUSCULUS MONOCLONAL DISULFIDE WITH IMMUNOGLOBULIN
  10. Drug

    Turoctocog alfa

    go.drugbank.com/drugs/DB09109
    Approved

    Turoctocog alfa is a recombinant factor VIII (rFVIII) with a truncated B-domain made from the sequence coding for 10 amino acids from the N-terminus and 11 amino acids from the C-terminus of the naturally occurring B-domain. Turoctocog a...